Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here’s Whether the Deal Is Worth It.
Key Points In the latest big-ticket deal in the pharmaceutical industry, Vertex Pharmaceuticals (NASDAQ:VRTX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) announced in…